4578   Otsuka Holdings Co.,Ltd.

07/26/2024 15:00	Notice Regarding Revisions of Consolidated Results Forecast for the first half of FY2024
07/05/2024 17:00	Corporate Governance Report 2024/07/05
06/25/2024 15:00	Otsuka and Lundbeck announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with PTSD
06/07/2024 13:00	Otsuka Announces the 4th Medium-Term Management Plan
05/29/2024 08:00	Otsuka and Lundbeck Present Results from Three Clinical Trials of Brexpiprazole in Combination with Sertraline for the Treatment of PTSD in Adults
05/22/2024 17:00	Notice Regarding Revisions of Consolidated Results for the first half of FY2024 and Impairment Loss for intangible assets
05/22/2024 17:00	Otsuka to Terminate Development of AVP-786
04/30/2024 13:30	Consolidated Financial Results for the First Quarter of the Fiscal Year Ending December 31, 2024[IFRS]
04/26/2024 16:00	Notice Concerning Completion of Payment for Disposal of Treasury Shares as Restricted Stock Compensation
04/23/2024 08:30	[Delayed]Corporate Governance Report
04/09/2024 15:00	Otsuka and Lundbeck submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD
03/28/2024 15:00	Notice Concerning Disposal of Treasury Shares as Restricted Stock Compensation
03/27/2024 17:00	Abilify Maintena 960 mg approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia
03/15/2024 15:30	Otsuka and Sumitomo Revise License Agreement
03/15/2024 08:00	Partial Correction to the Notice of the 16th Annual Shareholders Meeting (for FY2023)
02/28/2024 08:00	Notice of the 16th Annual Shareholders Meeting (for FY2023)
02/16/2024 15:30	[Delayed]Consolidated Financial Results for the Fiscal Year Ended December 31, 2023 [IFRS]
02/16/2024 11:00	[Delayed]Notice Regarding Revision of Restricted Stock Compensation Plan
02/16/2024 11:00	[Delayed]Notice of Introduction of a Special Incentive Scheme through the Otsuka Group Employee Stock Ownership Plan
02/14/2024 13:30	Notice of Payment of Dividends
02/13/2024 08:00	Notice Regarding Revisions of Consolidated Results Forecast for FY2023
12/22/2023 15:00	Otsuka Obtains the Additional Indication of Adjunctive Treatment of Major Depressive Disorder for Rexulti in Japan
12/01/2023 08:00	Pharmavite, a U.S. subsidiary of Otsuka Pharmaceutical, acquires Bonafide Health, a provider of women's health products
11/08/2023 08:30	Otsuka Medical Devices and Recor Medical Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension
11/06/2023 13:00	Otsuka Announces Personnel Changes
11/01/2023 00:30	Environmental report 2022
10/31/2023 13:30	Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending December 31, 2023[IFRS]
10/31/2023 13:00	Otsuka Applies in Japan for the Additional Indication for Agitation Associated with Dementia due to Alzheimer's Disease for Rexulti
10/31/2023 00:30	Integrated report 2022
09/07/2023 18:00	Otsuka and Lundbeck Announce Topline Results from Two P3 Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of PTSD
09/01/2023 08:00	Notice regarding transfer of sub-subsidiary
08/23/2023 10:00	OMD and Recor Announce Positive Vote from U.S. FDA Advisory Committee Meeting on the Paradise uRDN System for the Treatment of Hypertension
07/31/2023 13:30	Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending December 31, 2023 [IFRS]
07/31/2023 08:30	Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clinical Studies Evaluating Ulotaront in Schizophrenia